1. Home
  2. RGNX vs GALT Comparison

RGNX vs GALT Comparison

Compare RGNX & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo REGENXBIO Inc.

RGNX

REGENXBIO Inc.

N/A

Current Price

$7.26

Market Cap

487.2M

Sector

Health Care

ML Signal

N/A

Logo Galectin Therapeutics Inc.

GALT

Galectin Therapeutics Inc.

N/A

Current Price

$2.82

Market Cap

397.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RGNX
GALT
Founded
2008
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
487.2M
397.3M
IPO Year
2015
2008

Fundamental Metrics

Financial Performance
Metric
RGNX
GALT
Price
$7.26
$2.82
Analyst Decision
Strong Buy
Analyst Count
11
0
Target Price
★ $21.40
N/A
AVG Volume (30 Days)
★ 1.1M
178.4K
Earning Date
11-05-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
18.08
★ 36.84
EPS
N/A
★ N/A
Revenue
★ $10,393,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$24.01
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 126.48
N/A
52 Week Low
$5.46
$2.03
52 Week High
$16.19
$7.13

Technical Indicators

Market Signals
Indicator
RGNX
GALT
Relative Strength Index (RSI) 44.73 36.91
Support Level $6.79 $2.78
Resistance Level $7.32 $3.36
Average True Range (ATR) 0.59 0.29
MACD -0.03 -0.03
Stochastic Oscillator 15.40 8.33

Price Performance

Historical Comparison
RGNX
GALT

About RGNX REGENXBIO Inc.

Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.

About GALT Galectin Therapeutics Inc.

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.

Share on Social Networks: